Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
|
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion
    Hicks, J. Kevin
    Boyle, Theresa
    Albacker, Lee A.
    Madison, Russell
    Frampton, Garrett
    Creelan, Benjamin C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E148 - E150
  • [2] CLINICAL ACTIVITY OF CRIZOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING ROS1 GENE REARRANGEMENT
    Bang, Y. -J.
    Ou, S.
    Camidge, D. R.
    Clark, J. W.
    Wilner, K.
    Tye, L.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 33 - 33
  • [3] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
    Ou, Sai-hong I.
    Bang, Y-j
    Camidge, D. R.
    Engelman, J. A.
    Clark, J. W.
    Tye, L.
    Wilner, Keith
    Stephenson, P.
    Chung, D. H.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [4] Clinical Activity Of Crizotinib In Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement
    Shaw, A. T.
    Camidge, D.
    Clark, J. W.
    Wilner, K.
    Tye, L.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A.
    Ou, S. I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S208 - S209
  • [5] Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
    Yang, Guangdie
    Wang, Jie
    Yao, Yinan
    Zhao, Jun
    Yu, Zheyan
    Gao, Qiqi
    Ye, Jiani
    Ma, Wenjiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Engelman, Jeffrey A.
    Solomon, Benjamin J.
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Salgia, Ravi
    Shapiro, Geoffrey
    Bang, Yung-Jue
    Tan, Weiwei
    Tye, Lesley
    Wilner, Keith D.
    Stephenson, Patricia
    Varella-Garcia, Marileila
    Bergethon, Kristin
    Iafrate, A. John
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ROS1 GENE REARRANGEMENT
    Ou, S. I.
    Camidge, D. R.
    Engelman, J.
    Clark, J.
    Tye, L.
    Wilner, K.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 389 - 389
  • [8] Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
    Han, B.
    Zhang, B.
    Xu, J.
    Zhang, Y.
    Zhang, X.
    Chu, T.
    Wang, S.
    Qiao, R.
    Qian, J.
    Lu, J.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S471 - S471
  • [9] Patients Harboring a Novel PIK3CA Point Mutation after Acquired Resistance to Crizotinib in ROS1 Rearrangement Adenocarcinoma: A Case Report
    Fang, M.
    Wang, W.
    Xu, C.
    Liu, R.
    Liao, X.
    Zhu, Y.
    Du, K.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1893
  • [10] Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
    Shu, Yun
    Li, Hui
    Shang, Hongjuan
    Chen, Jun
    Su, Xiaoxing
    Le, Wei
    Lei, Yan
    Tao, Liming
    Zou, Cailiang
    Wu, Wendy
    ONCOTARGETS AND THERAPY, 2020, 13 : 10387 - 10391
12345